Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation

Angiology

Volumn 64, Issue 7, 2013, Pages 554-558

  Gao, Wen ^a   Zhang, Qinghua ^a   Ge, Hailong ^b   Guo, Yonghe ^b   Zhou, Zhiming ^b  

^a Bayannaoer City Hospital   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

clopidogrel; obesity; resistance antiplatelet

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL;

ADULT; ARTICLE; BLEEDING; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART DEATH; HEART INFARCTION; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; THROMBOCYTOPENIA;

CLOPIDOGREL; OBESITY; RESISTANCE ANTIPLATELET;

ADULT; AGED; ASPIRIN; BLOOD PLATELETS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS IMPLANTATION; STENTS; TETRAZOLES; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84883438261     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712474113     Document Type: Article

References (28)

1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res. 2005 ; 115 (1-2). 101-108
2. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is a associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004 ; 109 (25). 3171-3175
3. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet therapy activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol. 2004 ; 93 (4). 456-458
4. Muller I, Besta F, Schultz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Res. 2003 ; 89 (5). 783-787
5. Wang ZJ, Zhou YJ, Liu YY, et al. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res. 2009 ; 124 (1). 46-51
6. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003 ; 107 (23). 2908-2913
7. Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets. 2004 ; 15 (2). 95-99
8. Almsherqi ZA, McLachlan CS, Mossop P, Deng Y. Optimal antiplatelet treatment for precutaneous coronary intervention: clopidogrel vs. ticlopidine. Int J Cardiol. 2007 ; 114 (1). 101-102
9. Wang ZJ, Zhou YJ, Liu YY, et al. Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents. Heart. 2009 ; 95 (19). 1587-1592
10. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. Platelet aggregation according to BMI in patients undergoing coronary stenting: should clopidogrel loading dose be weight adjusted?. J Invasive Cardiol. 2004 ; 16 (4). 169-174
11. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007 ; 49 (24). 2312-2317
12. Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol. 2007 ; 120 (2). 188-192
13. Tamminen M, Lassila R, Westerbacka J, et al. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord. 2003 ; 27 (8). 907-911
14. Ferro-Luzzi A, Garza C, Haas J, et al. Physical status: the use interpretation of anthropometry: report of a WHO Expert Committee. WHO Tech Rep Ser. 1995 ; 854 (1). 1-452
15. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007 ; 116 (25). 2923-2932
16. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol. 1998 ; 31 (7). 1466-1473
17. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994 ; 31 (3). 29-39
18. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005 ; 45 (9). 1392-1396
19. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting. J Am Coll Cardiol. 2005 ; 46 (10). 1833-1837
20. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006 ; 4 (3). 542-549
21. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. Circulation. 2009 ; 119 (2). 237-242
22. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007 ; 49 (24). 2312-2321
23. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the prepare poststenting study. J Am Coll Cardiol. 2005 ; 46 (10). 1820-1826
24. Ajzenberg N, Aubry P, Huisse MG, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol. 2005 ; 45 (11). 1753-1756
25. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005 ; 6 (4). 3-11
26. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985 ; 35 (7A). 1144-1149
27. Ch KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2009 ; 119 (25). 3207-3214
28. Lee SW, Chun KJ, Park SW, et al. Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol. 2010 ; 105 (2). 168-173